



(51) International Patent Classification:

A61P 35/00 (2006.01) C07K 16/30 (2006.01)
C07K 16/28 (2006.01) C07K 16/40 (2006.01)

(21) International Application Number:

PCT/EP2018/079785

(22) International Filing Date:

31 October 2018 (31.10.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

17199537.6 01 November 2017 (01.11.2017) EP

(71) Applicant (for all designated States except US): **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH).

(71) Applicant (for US only): **HOFFMANN-LA ROCHE INC.** [US/US]; Overlook at Great Notch, 150 Clove Road, 8th Floor, Suite 8 - Legal Department, Little Falls, New Jersey 07424 (US).

(72) Inventors: **AMANN, Maria**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **FERRARA KOLLER, Claudia**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **FLURY, Reto**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **GEORGES, Guy**; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). **GRAU-RICHARDS, Sandra**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **HAAS, Alexander**; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). **HESSE, Friederike**; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). **IMHOF-JUNG, Sabine**; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). **KLEIN, Christian**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH).

(74) Agent: **KLOSTERMEYER RAUBER, Doerte**; Grenzacherstrasse 124, 4070 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

(54) Title: BISPECIFIC 2+1 CONTORSBODIES




Fig. 1C




Fig. 1D

(57) Abstract: The invention relates to novel bispecific antibodies consisting of two fusion polypeptides comprising two antigen binding domains capable of specific binding to a first target and one antigen binding domain capable of specific binding to a second target, and to methods of producing these molecules and to methods of using the same.

[Continued on next page]

HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

29 August 2019 (29.08.2019)